ALXO

ALX Oncology Holdings Inc.

8.45 USD
-0.11 (-1.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ALX Oncology Holdings Inc. stock is down -44.3% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 May 19:30 16 Aug, 2024 13.00 CALL 65 1
16 May 15:38 16 Aug, 2024 16.00 PUT 64 196
16 May 15:39 16 Aug, 2024 16.00 PUT 66 196
30 May 15:22 19 Jul, 2024 12.00 PUT 200 0
04 Jun 16:29 16 Aug, 2024 15.00 PUT 40 92
04 Jun 16:50 15 Nov, 2024 9.00 CALL 100 0
05 Jun 16:45 15 Nov, 2024 10.00 CALL 100 1
05 Jun 18:18 21 Jun, 2024 13.00 PUT 201 501
06 Jun 14:23 16 Aug, 2024 5.00 CALL 50 0
06 Jun 14:49 16 Aug, 2024 5.00 CALL 84 0

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

  • HC Wainwright & Co.
    Mon Jun 10, 06:56
    buy
    confirm
  • Cantor Fitzgerald
    Wed May 29, 09:13
    buy
    confirm